Quick Answer
Neumora Therapeutics, Inc. reported Diluted EPS of $1.45 per share (loss) for fiscal year 2025.
Neumora Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.45 | +5.2% |
| 2024 | -$1.53 | +57.9% |
| 2023 | -$3.63 | +24.5% |
| 2022 | -$4.81 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.35 | +22.2% | -6.1% |
| June 30, 2025 | -$0.33 | +10.8% | +21.4% |
| March 31, 2025 | -$0.42 | -23.5% | +6.7% |
| September 30, 2024 | -$0.45 | +60.5% | -21.6% |
| June 30, 2024 | -$0.37 | +71.1% | -8.8% |
| March 31, 2024 | -$0.34 | +72.1% | +70.2% |
| September 30, 2023 | -$1.14 | -7.5% | +10.9% |
| June 30, 2023 | -$1.28 | — | -4.9% |
- Neumora Therapeutics, Inc. showed an increase of +5.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Neumora Therapeutics, Inc.’s diluted eps has grown by 69.9% (from $4.81 per share (loss) to $1.45 per share (loss)).
- The most recent figure is from Neumora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: